Medpace Q3 revenue rises 8.5%, slightly beats analyst estimates

Overview

• US clinical research firm's Q3 revenue rose 8.5%, slightly beating analyst expectations

• Q3 net income grew to $137.5 mln, with net income margin rising to 19.2%

• Company approved new $1 bln share repurchase authorization, replacing prior program

Outlook

• Medpace forecasts 2026 revenue of $2.835 bln to $2.855 bln

• Company expects 2026 GAAP net income of $514 mln to $524 mln

• Medpace projects 2026 diluted EPS of $17.97 to $18.32

Result Drivers

• NEW BUSINESS AWARDS - Net new business awards rose 10.6% year-on-year to $873.4 mln, supporting revenue growth

Company press release:

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 12 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Medpace Holdings, Inc. is $615.00, about 1.2% below its October 20 closing price of $622.43

• The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 30 three months ago

Reuters Recommended Reads

• Oct 20 - RTX beats Q3 earnings expectations, lifts guidance amid robust demand

• Oct 21 - Thermo Fisher Q3 revenue, adj profit beat estimates after new product launches

• Oct 21 - Danaher Q3 adjusted EPS beats, FY guidance raised

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)